Vasodilation

Bestqool proves the effectiveness and safety of its red light therapy device with a professional third-party Report

Retrieved on: 
Wednesday, April 17, 2024
Physical, Enzyme, Cell, RLT, Safety, Skin, Tissue, Bacteria, NASA, Weight loss, System, Carbon, Plant, Mitochondrion, Oxygen, Phagocytosis, Vasodilation, Medicine, Virus, Nutrient, Regeneration, Food preservation

Bestqool , a leading manufacturer in the industry of red light therapy, offers lifestyle game-changing devices that prioritize safety, efficacy, and user comfort.

Key Points: 
  • Bestqool , a leading manufacturer in the industry of red light therapy, offers lifestyle game-changing devices that prioritize safety, efficacy, and user comfort.
  • The utilization of red light therapy in well-being has its roots dating back to ancient Greek times.
  • Unlike ultraviolet light, red light is harmless to the skin and does not tan or cause dark spots to the skin.
  • One of the crucial factors that the reader needs to pay attention to when buying red light therapy is RLT device irradiance.

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

Retrieved on: 
Monday, March 25, 2024
Shift, Protein kinase B, Cardiology, Stroke, Health, Myocardial infarction, SGLT1, Chronic kidney disease, CKD, Risk, Theatre, Endothelium, Inflammation, Knowledge, SGLT2, Diabetes, HF, University of Colorado, Vessel, University of Michigan, Inhibitor, University, Coagulation, Protein, GDMT, Heart failure, American College, Type 2 diabetes, Vasodilation, Food, Hospital, Pharmaceutical industry

In a post-hoc analysis of data from the 10,584 patients in the SCORED Phase 3 clinical trial, 213 all-cause stroke events occurred, including 29 (13.6%) fatal events.

Key Points: 
  • In a post-hoc analysis of data from the 10,584 patients in the SCORED Phase 3 clinical trial, 213 all-cause stroke events occurred, including 29 (13.6%) fatal events.
  • Sotagliflozin reduced the risk of all-cause stroke by 34%, with 1.2 events per 100 patient-years in the sotagliflozin group and 1.8 events per 100 patient-years in the placebo group.
  • Similarly, sotagliflozin reduced the risk of ischemic stroke by 32%, with 0.8 events per 100 patient-years in the sotagliflozin group and 1.2 events per 100 patient-years in the placebo group.
  • Candidate, University of Michigan, Ann Arbor, Michigan
    Study researchers found that sotagliflozin inhibits platelet activation through simultaneously targeting SGLT1 and SGLT2.

Korea Ginseng Corporation Revealed 'EVERYTIME' in New Grapefruit Flavor & 'Rev Your Life' Campaign at 2024 Natural Products Expo West

Retrieved on: 
Monday, March 18, 2024
Research, Health, Taste, System, Patient, Food, Ginseng, Drink, Vasodilation, Heart, Snack, Marketing, Movement

At the 2024 Natural Products Expo West, JungKwanJang, the world's number one ginseng brand, unveiled a new grapefruit flavor for the global representative ginseng product EVERYTIME to redefine industry standards.

Key Points: 
  • At the 2024 Natural Products Expo West, JungKwanJang, the world's number one ginseng brand, unveiled a new grapefruit flavor for the global representative ginseng product EVERYTIME to redefine industry standards.
  • Ginseng, a revered medicinal ingredient, has a rich history spanning over 2,000 years and is celebrated for its disease-prevention and health-boosting properties.
  • Along with the new EVERYTIME grapefruit flavor, JungKwanJang introduced their 2024 marketing slogan 'Rev Your Life' at NPEW.
  • The Natural Products Expo West was an exciting and successful showcase for JungKwanJang's latest product this year.

Tectonic Therapeutic Announces Start of First Clinical Program for GPCR-Targeted Biologic

Retrieved on: 
Tuesday, November 28, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, RXFP1, Vasodilation, Tissue, Patient, Pregnancy, Protein engineering, System, MD, Harvard Medical School, Relaxin, GPCR, Doctor of Philosophy, Naval Hospital Boston, Inflammation, Fibrosis, Pharmaceutical industry

“The start of our first-in-human study is a critical and exciting milestone.

Key Points: 
  • “The start of our first-in-human study is a critical and exciting milestone.
  • We look forward to seeing the potential of relaxin biology realized in patients,” said Alise Reicin, MD, President and Chief Executive Officer, Tectonic Therapeutic.
  • Because of these features, it offers a similarly broad range of potential therapeutic applications with significant benefits expected in cardio-pulmonary diseases.
  • We look forward to future clinical programs emerging from Tectonic’s platform.”

Vibrato Medical Announces Positive Results for Early Feasibility Study of Wearable, Non-Invasive Therapeutic Ultrasound to Treat Chronic Limb-Threatening Ischemia (CLTI)

Retrieved on: 
Wednesday, November 1, 2023
Health, Medical Devices, Radiology, Clinical Trials, Research, Science, Cardiology, Blood vessel, TUS, Patient, Heart, Chronic limb threatening ischemia, Medicine, Vasodilation, CLTI, Perfusion, Vibrato, Ischemia, Claudication, Moyamoya disease, Disease, Orange County, VIVA, Amputation, PAD, Perception, Wynn Las Vegas, Prelude, Medical imaging, Pharmaceutical industry, MD

Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that data from an early feasibility study of Non-Invasive Therapeutic Ultrasound (TUS) to treat Chronic Limb-Threatening Ischemia (CLTI) has successfully met its endpoint.

Key Points: 
  • Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that data from an early feasibility study of Non-Invasive Therapeutic Ultrasound (TUS) to treat Chronic Limb-Threatening Ischemia (CLTI) has successfully met its endpoint.
  • The study evaluated patients with infrapopliteal PAD and measured changes in foot perfusion and oxygenation as well as therapy tolerance, compliance and perception.
  • Patients in the trial had Rutherford class 3, 4 or 5 PAD, meaning severe claudication, ischemic rest pain or tissue loss including nonhealing ulcers.
  • “These early findings are promising for the future of non-invasive therapeutic options to treat chronic limb-threatening ischemia,” said Juliana Elstad, CEO at Vibrato.

Mangoceuticals Announces TV Air Dates for Interview Featuring CEO Jacob Cohen on Bloomberg TV and Fox Business

Retrieved on: 
Friday, October 13, 2023
Sildenafil, Tadalafil, Traction, Vasodilation, Arginine, Bloomberg Television, Mouth, Adam22, Growth, International, Marketing, New Haven State Street station, Fox Business, Tongue, Erectile dysfunction, Interview, FMW, Oxytocin, Barstool Sports, Television, Retail

In the interview, Mr. Cohen begins by laying out the Company’s potent strategy for differentiating itself as a new breed of men’s health product provider.

Key Points: 
  • In the interview, Mr. Cohen begins by laying out the Company’s potent strategy for differentiating itself as a new breed of men’s health product provider.
  • According to Cohen, it starts with the idea of an “Erectile Function” pill instead of an “Erectile Dysfunction” pill.
  • Through that idea, Cohen believes the Company is positioning itself to tap into the relatively untapped younger demographic, which is mirrored by MangoRx’s dynamic marketing strategy.
  • Through its network of syndication, FMW programming reaches an estimated 540 million homes across US and international markets.

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease

Retrieved on: 
Tuesday, September 26, 2023
Apolipoprotein E, CAA, Cerebral amyloid angiopathy, Drug discovery, DSM-IV codes, APOE4, Cancer, Inflammation, Washington University in St. Louis, Dementia, Vasodilation, BBB, Ischemia, Amyloid, Risk, Mouse, AD, APOE, Conference, Disease, Pharmaceutical industry, Vaccine, Medical imaging, Neurology

Deletion of APOE has been demonstrated to limit disease in multiple AD models.

Key Points: 
  • Deletion of APOE has been demonstrated to limit disease in multiple AD models.
  • In preclinical AD animal models, NC181 has demonstrated differentiation from amyloid targeted therapies.
  • Key findings from the study include:
    NC181 binds to amyloid associated ApoE4, resulting in amyloid clearance and prevention of amyloid deposition in mice.
  • Additional studies to characterize NC181 as a potential therapeutic for AD and CAA are ongoing.

Hi-Tech Pharmaceuticals Launches KRANK3D® Pre-Workout Supplement

Retrieved on: 
Tuesday, August 1, 2023
Taste, HCL, High, Marketing, Enzyme, Innovation, NOS, Nitro, Wheat, Armindo Cadilla, Research and development, Vasodilation, Athlete, Nitric oxide, NO, Performance, Head, Agmatine, High tech, Arginase, BEC, Ultimate, Gummy candy, Arginine, Fine chemical, Research

This Hi-Tech exclusive technology leaves an abundance of L-arginine uncompromised in the muscle pool to create a wealth of NO, leading to maximum muscular vasodilation.

Key Points: 
  • This Hi-Tech exclusive technology leaves an abundance of L-arginine uncompromised in the muscle pool to create a wealth of NO, leading to maximum muscular vasodilation.
  • We believe that it will quickly become the go-to pre-workout supplement for aspiring athletes and gym goers looking to take their training to the next level."
  • "KRANK3D® is an innovative, intense, wicked pre-workout energy supplement that will be the Cadillas of our preworkout stable, which includes: Mesomorph®, Jack3D®, Ultimate Orang®, and Wicked®.
  • Not only does this new state-of-the-art formula hit harder, it also tantalizes your taste buds like never before.

Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Retrieved on: 
Monday, June 5, 2023
Cream, Pros, SST, Female, Prevalence, Marketing, PRO, International Society of Sculptors, Painters and Gravers, Orgasm, OBGYN, Woman, Research, Trial of the century, Vasodilation, University Hospitals Cleveland Medical Center, Arousal, Patient, Textbook, SAN, Pleasure, Behavioral medicine, Human, Erectile dysfunction, FDA, Safety, Diagnosis, Treatment, Medical imaging, Pharmaceutical industry, Birth control, FSAD

SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced positive topline data from the exploratory Phase 2b RESPOND study evaluating topical Sildenafil Cream, 3.6% (Sildenafil Cream) as a treatment for female sexual arousal disorder (FSAD). The exploratory study was designed to test the sensitivity of several patient reported outcome (PRO) efficacy endpoints and their ability to determine a treatment effect of Sildenafil Cream compared to placebo to inform the ongoing development of Sildenafil Cream. The study also served as a validation study of exploratory endpoints that could be candidate endpoints in a Phase 3 study of Sildenafil Cream. Although the exploratory study was underpowered to assess statistical significance, certain endpoints achieved statistical significance.

Key Points: 
  • The study also served as a validation study of exploratory endpoints that could be candidate endpoints in a Phase 3 study of Sildenafil Cream.
  • Sildenafil Cream is an investigational proprietary topical cream formulation of sildenafil specifically designed to increase blood flow to the genital tissue in women.
  • “We are very pleased with the topline data from the Phase 2b RESPOND study.
  • Daré plans to submit data from the Phase 2b RESPOND clinical study of Sildenafil Cream for publication in a peer-reviewed journal.

Daré Bioscience Announces Availability of Publication on the Patient-Centered Concept Elicitation Study for Female Sexual Arousal Disorder in The Journal of Sexual Medicine

Retrieved on: 
Wednesday, May 31, 2023
Cream, SST, Hypoactive sexual desire disorder, Female, Prevalence, Safety, Efficacy, PRO, Trial of the century, FSAD, Woman, Vasodilation, Arousal, Journal, Patient, Article, Erectile dysfunction, FDA, HSDD, ED, Medical imaging, Pharmaceutical industry, Birth control

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the publication of results of the patient-centered study designed to elucidate the commonly reported symptoms, including severity of symptoms, associated with female sexual arousal disorder (FSAD). The publication, “Symptoms and associated impact in pre-and postmenopausal women with sexual arousal disorder: a concept elicitation study,” appears in The Journal of Sexual Medicine.

Key Points: 
  • The publication, “Symptoms and associated impact in pre-and postmenopausal women with sexual arousal disorder: a concept elicitation study,” appears in The Journal of Sexual Medicine.
  • The non-interventional study was conducted to identify and document the genital arousal symptoms that are the most problematic and most important symptoms to treat for women with FSAD.
  • The content validity study included in-depth, qualitative, semi-structured concept elicitation interviews with premenopausal (n=23) and postmenopausal (n=13) women who were clinically diagnosed with FSAD by a trained sexual medicine clinician.
  • FSAD is distinct from hypoactive sexual desire disorder (HSDD) in women, which is characterized primarily by a lack of sexual desire.